Amy L. Billett, MD
Director of Safety and Quality, Division of Pediatric Hematology/Oncology
Associate Professor of Pediatrics, Harvard Medical School
Electronic health records, Global health, Lymphoma (Hodgkin and Non-Hodgkin), Management of nausea and vomiting, Patient safety, Quality improvement
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Pediatric Hematology/Oncology, 2001
Boston Children's Hospital/Dana-Farber Cancer Institute, Pediatric Hematology/Oncology, 1990
University of Washington Hospitals
Children's Hospital and Medical Center
Harvard Medical School, 1984
Dr. Billett received her MD from Harvard Medical School in 1984. After completing a residency in pediatrics at the University of Washington Hospitals, she completed a fellowship in pediatric hematology-oncology at Children's Hospital Boston and Dana-Farber Cancer Institute and became a staff physician in the pediatric hematology/oncology program in 1990. She was the medical director of the inpatient oncology service at Children's Hospital 1995-2005.
Dr. Billett has participated in multiple projects involving improving systems of care, including development of a pediatric chemotherapy order entry system, implementation of the joint CH-DFCI pediatric electronic health record. She is currently the medical director for patient safety and quality in the pediatric hematology/oncology program, the leader of the pediatric lymphoma program, and an active clinician in the program.
She is a clinical faculty leader of the newly established national collaborative to reduce catheter-associated blood stream infections in pediatric hematology/oncology patients.
Hodgkin's Disease in Children, CLABSI-reduction
Our program has been an active member of a small national consortium for clinical trials in pediatric Hodgkins since 1990. pediatric Hodgkin's disease. We currently have three open trials looking at improving/maintaining efficacy while minimizing long-term toxicity.Our center is a founding member of a national quality improvement collaborative started in 2009 to reduce catheter-associated blood stream infections in pediatric hematology-oncology patients. The focus of the collaborative is reliable implementation of best central line maintenance care.